Natriuretic peptides have been identified as potential biomarkers for cardiac injury that precedes heart failure for their role in vasodilation, anti-inflammation, and natriuresis. Measurement of these biomarkers in animal models presents possible solutions for screening, diagnosis, prognosis, and therapeutic management of cardiovascular disease.
MSD offers an assay for the quantitative determination of endogenous N-terminal pro-atrial natriuretic peptide (NT-ProANP), a secreted prohormone that has been shown to be a useful diagnostic and prognostic tool in heart failure and myocardial infarction.